HTB

PK and drug interactions

D/C/F/TAF: no impact on bioavailability of when tablet split but TAF reduced when crushed

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Dolutegravir pharmacokinetics in pregnancy

FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

New HIV diagnoses in children in UK and Ireland continue to decline

World Health Organisation paediatric dosing tool

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

Nevirapine dosing for treatment of neonates

Pharmacokinetics of old and new TB drugs for children

The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression

Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB

Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel

Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives

Pharmacokinetics of four antiretrovirals in pregnancy: data from the PANNA network

Dolutegravir placental transfer moderate in ex vivo model

Paediatric dosing of DRV/r

Elvitegravir in children and adolescents

PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir

Pharmacokinetics in pregnancy: darunavir/r and etravirine

Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Pharmacokinetics and safety of moxifloxacin in children

Equivalent efficacy with lower dose darunavir

Pharmacokinetic targets for efavirenz might be too high

Preventing and treating TB in children – more baby steps

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above

Bilirubin as a surrogate marker for atazanavir in children

Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

Tenofovir population pharmacokinetics in pregnancy

Effect of rifampicin on BMS-663068 in HIV negative volunteers

Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting

Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)

Paediatric TB: glimpses of PK data and a potential new approach to drug development

Efavirenz interaction studies with TB compounds bedaquiline and delamanid

Ritonavir significantly increases exposure to colchicine (gout)

Ritonavir interaction with quinine is clinically insignificant but may warrant caution

Case report: fluticasone, fluconazole and ritonavir interactions

Case reports of complications from ketamine use in two MSM on ritonavir-based combinations

Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations

13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona

Studies on pipeline ARVs

Washout pharmacokinetics of transplacental raltegravir in neonates

Interactions between malaria drugs and etravirine or darunavir/r

No interaction between antimalarial amodiaquine and nevirapine

Pharmacokinetics of atazanavir/ritonavir plus raltegravir

Atazanavir/ritonavir and voriconazole not to be coadministered

Milk thistle (silymarin) and darunavir/ritonavir

Echinacea and etravirine

Warfarin and ARVs: impact of African American race and ritonavir

Darunavir use during pregnancy

FDA warning of drug interactions between boceprevir and some HIV protease inhibitors

Interactions between nevirapine and antimalarials (artemether and lumefantrine)

Interactions between antiretrovirals and complementary and African traditional medicines

Drug interactions between sirolimus (rapamycin) and ARVs

Contraceptive failure with etonogestrel implants and efavirenz: case reports

Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients

Ritonavir levels reduced with high fat meal

Post navigation